文献速递临床试验与 GCP

物理治疗与药物管理对新冠感染后肌痛性脑脊髓炎患者的疲劳、躯体功能和发作性残疾的疗效比较:随机对照试验研究方案

Comparing effectiveness of physiotherapy versus drug management on fatigue, physical functioning, and episodic disability for myalgic encephalomyelitis in post-COVID-19 condition: a study protocol of randomized control trial.
PubMed 文献 · Trials · 2024-05-15

本研究计划纳入135例新冠感染后伴有肌痛性脑脊髓炎/慢性疲劳综合征的病例,采用三臂前瞻性随机对照设计,比较机构内适应性体力活动与治疗性运动、远程医疗版相同干预与药物管理的效果;主要结局为疲劳(Chalder疲劳量表),次要结局为躯体功能(SF-36)和发作性残疾(伤残调整生命年),干预2个月后评估、干预后6个月随访。

要点

  • 三臂随机对照试验比较物理治疗(机构内与远程医疗)与药物管理对新冠感染后ME/CFS的疗效。
  • 计划纳入135例新冠感染后ME/CFS病例,按1:1:1分组,干预2个月后评估、6个月随访。
  • 主要结局为Chalder疲劳量表,次要结局为SF-36和伤残调整生命年。

核心结论

  • 本研究旨在填补物理治疗与药物管理对新冠感染后ME/CFS疗效比较的研究空白,为新冠感染后康复的循证实践提供依据。

研究设计与样本

  • 三臂前瞻性随机对照试验,计划纳入135例2023年11月20日至2024年5月20日期间从人群队列中诊断的新冠感染后ME/CFS病例。
  • 参与者采用隐蔽分配和区组随机化按1:1:1比例分为三组:机构内适应性体力活动与治疗性运动、远程医疗版适应性体力活动与治疗性运动、药物管理。
  • 干预2个月后进行治疗后评估,干预后6个月进行随访。

主要发现

  • 主要结局采用Chalder疲劳量表测量疲劳。
  • 次要结局采用SF-36测量躯体功能,采用伤残调整生命年(DALYs)测量发作性残疾。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Physiotherapy interventions effectively improved fatigue and physical functioning in non-COVID patients with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). There is a research gap on the effectiveness of physiotherapy interventions versus drug management on ME/CFS in post-COVID-19 conditions (PCC). METHODS: We planned a three-arm prospective randomized control trial on 135 PCC cases with ME/CFS who are diagnosed between 20 November 2023 and 20 May 2024 from a population-based cohort. The study aims to determine the effectiveness of physiotherapy interventions as adapted physical activity and therapeutic exercise (APTE) provided in institution-based care versus telemedicine compared with drug management (DM). Participants will be assigned to three groups with the concealed location process and block randomization with an enrollment ratio of 1:1:1. The post-treatment evaluation will be employed after 2 months of interventions, and follow-up will be taken after 6 months post-intervention. The Chalder fatigue scale will measure the primary outcome of fatigue. SF-36 and the disability-adjusted life years (DALYs) will measure the secondary outcome of physical functioning and episodic disability. DISCUSSION: This study will address the research gap to determine the appropriate approach of physiotherapy or drug management for ME/CFS in PCC cases. The future direction of the study will contribute to developing evidence-based practice in post-COVID-19 condition rehabilitation. TRIAL REGISTRATION: The trial is registered prospectively from a primary Clinical Trial Registry side of WHO CTRI/2024/01/061987. Registered on 29 January 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sarker AH, Hossain KMA, Kabir MF, et al. Comparing effectiveness of physiotherapy versus drug management on fatigue, physical functioning, and episodic disability for myalgic encephalomyelitis in post-COVID-19 condition: a study protocol of randomized control trial. Trials. 2024. PMID: 38750586. doi:10.1186/s13063-024-08077-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。